Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported its financial results for the quarter- and year-ended December 31, 2017 and provided ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Corcept Therapeutics (CORT) Reports Q4 EPS of $0.77February 22, 2018 4:09 PM Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 TrialFebruary 22, 2018 4:05 PM